Amgen
Developing innovative human therapeutics
- B2B
- B2C
- Has physical offices
- Publicly traded
- Manufacturing
- Multi-product
- Sales-led purchase
About Amgen
This biotechnology company focuses on discovering and developing innovative therapeutics to improve health outcomes for patients with serious illnesses worldwide
Key facts
- Industry
- Biotechnology Research
- Company size
- 10,000+ employees
- Headquarters
- Thousand Oaks, California, United States
- Founded
- 1980
- Revenue
- $36.8BFY2025, publicly reported
- SIREN
- 377998679
- Website
- amgen.com
- linkedin.com/company/amgen
Amgen competitors
Jobs at Amgen
- Senior Director, Head Launch Excellence
- Artwork Reviewer - Global Artwork
- Global Pharmacovigilance (PV) Scientist, Manager- Oncology
- Artwork Designer - Global Artwork
- Global Value & Access Senior Manager (Flexible Location: Argentina, Colombia, Mexico City)
- Global Safety Medical Director, Rare Disease
- Artwork Strategist - Global Artwork
- Associate Director, Data Strategy and Governance
Amgen in the news
- Amgen stock faces a USD 400 Cantor Fitzgerald target
Amgen's stock received a Neutral rating from Cantor Fitzgerald with a USD 400 target, while its Q2 revenue increased by 9.5% to USD 10.05 billion.
- 2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC
Argent Capital Management LLC sold 2,546 shares of Amgen Inc., while other institutional investors made minor adjustments to their holdings, and analysts provided new price targets.
- Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances?
Amgen is focusing on a late-stage obesity drug candidate featuring a once-quarterly dosing, leveraging its biologics expertise amidst a competitive market, and discontinuing an earlier program.
- Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
Cantor Fitzgerald reiterated a Neutral rating on Amgen, citing strong commercial execution and a quiet catalyst calendar through year-end 2026, while Amgen also announced successful Phase 3 trial results for dazodalibep in Sjögren’s disease.
- Amgen (NASDAQ:AMGN) Stock Purchase Disclosed by Rep. David Taylor
Representative David Taylor purchased Amgen shares between $1,001 and $15,000 on September 22nd, with the company also reporting strong earnings, a dividend, and significant institutional ownership.
Amgen at a glance
Amgen is a B2B/B2C company in the Biotechnology Research industry, headquartered in Thousand Oaks, California, United States.
Amgen was founded in 1980.
Amgen has 10,000+ employees.
Amgen's revenue is $36.8B (FY2025, publicly reported).
Amgen's SIREN number is 377998679.
Amgen is hiring: 8 recent open roles, including Senior Director, Head Launch Excellence, Artwork Reviewer - Global Artwork, Global Pharmacovigilance (PV) Scientist, Manager- Oncology.
Selling to companies like Amgen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies